Characterizing the immune landscape in newly diagnosed epithelial ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the immune landscape of newly diagnosed epithelial ovarian cancer by enrolling patients in four distinct cohorts based on their treatment plans. Patients will either undergo primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery, with a focus on both common and rare subtypes of the cancer. Additionally, a cohort of women undergoing adnexectomy for benign conditions will be included for comparative analysis. Biological samples, including tumor samples and blood, will be collected at specified time points to facilitate the study's objectives.

Why it matters

Who can join: the full rules

Inclusion criteria cohort A-D:

* Suspicious diagnosis of epithelial ovarian cancer (subsequent histologically confirmation required)
* Plan to undergo a surgical procedure for the management of epithelial ovarian cancer or recurrent ovarian cancer previously treated with conventional treatment and involved in the trial as group A-D
* ≥18 years old
* ECOG Performance Status ≤ 2
* Written informed consent

Inclusion criteria cohort E:

* Indication for adnexectomy for a benign gynecological condition
* ≥18 years old
* ECOG Performance Status ≤ 2
* Written informed consent

Exclusion criteria cohort A-E:

* Other active concomitant neoplasms that might confound the results of the planned analysis.
* Ongoing active autoimmune disease requiring treatment or condition of immune deficiency
* Ongoing chronic treatment with steroids or other immune suppressive agents at the time of study entry

Where it's running

• Oncology Institute of Southern Switzerland
  Bellinzona, Switzerland Recruiting

Study contacts

• Study coordinator: Ilaria Colombo, MD
• Email: ilaria.colombo@eoc.ch
• Phone: +41764528823

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• Whole-body metabolic activity as a predictor of chemotherapy response in epithelial ovarian cancer

  This study tests whether whole-body metabolic activity can predict how well epithelial ovarian cancer responds to chemotherapy.

  Recruiting University of Tennessee Graduate School of Medicine · Knoxville, Tennessee · NCT07764133

• [68Ga]BED003 PET imaging to see fibroblast activity in selected cancers

  This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.

  Recruiting at 5 sites Phase 2 Blue Earth Diagnostics · Bergamo, Lombardy and 5 other locations · NCT07702292

• Dual-target CAR-NK Cells for Peritoneal Cancers of the Ovary, Fallopian Tube, or Pseudoperitoneal Disease

  This trial tests a dual-target CAR-NK cell therapy for people with recurrent or hard-to-treat epithelial ovarian, fallopian tube, or primary peritoneal cancer who express two or more specific tumor markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617753

• Dual-Target CAR-NK Cells for Recurrent or Refractory Epithelial Ovarian Cancer

  This trial tests EB-DUALNK, a dual-target CAR-NK cell therapy, in adults with recurrent or refractory epithelial ovarian, fallopian tube, or peritoneal cancer to see if it can safely help the cancer shrink or stay controlled.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07589543

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.